Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rPV vs IPOL in Healthy Adults
NCT07688369Phase 1Recruiting
- Sponsor
- Serum Institute of India
- Start
- Sep 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CS-2036 in poliomyelitis (2 arms), sponsored by Serum Institute of India. Primary endpoint: Adverse Events at 30 days. Started Sep 2026; status: recruiting.
02
Drugs
CS-2036
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT07688369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07688369.